HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Regensteiner, J. G. Articles by Reusch, J. E.B. Search for Related Content PubMed PubMed Citation Articles by Regensteiner, J. G. Articles by Reusch, J. E.B. Related Collections Related Article Editorial Social Bookmarking                What's this?

Rosiglitazone Improves Exercise Capacity in Individuals With Type 2 Diabetes

¹ Divisions of Internal Medicine and Cardiology and the Center for Women’s Health Research, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado
² Division of Endocrinology and the Center for Women’s Health Research, Department of Medicine, University of Colorado Health Sciences Center, Veterans Administration Medical Center, Denver, Colorado

Address correspondence and reprint requests to Judith G. Regensteiner, PhD, Professor of Medicine, Box B-180, University of Colorado Health Sciences Center, 4200 E. 9th Ave., Denver, CO 80262. E-mail: judy.regensteiner{at}uchsc.edu

OBJECTIVE—Although exercise is recommended as a cornerstone of treatment for type 2 diabetes, it is often poorly adopted by patients. We have noted that even in the absence of apparent cardiovascular disease, persons with type 2 diabetes have an impaired ability to carry out maximal exercise, and the impairment is correlated with insulin resistance and endothelial dysfunction. We hypothesized that administration of a thiazolidinedione (TZD) agent would improve exercise capacity in type 2 diabetes.

RESEARCH DESIGN AND METHODS—Twenty participants with uncomplicated type 2 diabetes were randomly assigned in a double-blind study to receive either 4 mg/day of rosiglitazone or matching placebo after baseline measurements to assess endothelial function (brachial artery diameter by brachial ultrasound), maximal oxygen consumption (O_2max), oxygen uptake (O₂) kinetics, and insulin sensitivity by hyperinsulinemic-euglycemic clamp. Measurements were reassessed after 4 months of treatment.

RESULTS—Participant groups did not differ at baseline in any measure. Rosiglitazone-treated participants (n = 10) had significantly improved O_2max (19.8 ± 5.3 ml · kg^–1 · min^–1 before rosiglitazone vs. 21.2 ± 5.1 ml · kg^–1 · min^–1 after rosiglitazone, P < 0.01), insulin sensitivity, and endothelial function. A change in O_2max correlated with improved insulin sensitivity measured by clamp (r = 0.68, P < 0.05) and with improved brachial artery diameter (r = 0.70, P < 0.05). Placebo-treated participants (n = 10) showed no changes in O_2max (19.4 ± 5.2 ml · kg^–1 · min^–1 before rosiglitazone vs. 18.1 ± 5.3 ml · kg^–1 · min^–1 after rosiglitazone, NS) or brachial artery diameter.

CONCLUSIONS—This is the first known report showing that a TZD improved exercise function in type 2 diabetes. Whether this is due to the observed improvements in insulin sensitivity and/or endothelial function or to another action of the TZD class requires further exploration.

Abbreviations: CWR, constant work rate • DEXA, dual-energy X-ray absorptiometry • HOMA-IR, homeostasis model assessment of insulin resistance • TZD, thiazolidinedione

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles:

Why Might Thiazolidinediones Increase Exercise Capacity in Patients With Type 2 Diabetes?

Nathan K. LeBrasseur and Neil B. Ruderman
Diabetes Care 2005 28: 2975-2977. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				I. Pagel-Langenickel, D. R. Schwartz, R. A. Arena, D. C. Minerbi, D. Thor. Johnson, M. A. Waclawiw, R. O. Cannon III, R. S. Balaban, D. J. Tripodi, and M. N. Sack A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2659 - H2666. [Abstract] [Full Text] [PDF]

				P. W. Franks, R. J. F. Loos, S. Brage, S. O'Rahilly, N. J. Wareham, and U. Ekelund Physical activity energy expenditure may mediate the relationship between plasma leptin levels and worsening insulin resistance independently of adiposity J Appl Physiol, May 1, 2007; 102(5): 1921 - 1926. [Abstract] [Full Text] [PDF]

				N. K. LeBrasseur and N. B. Ruderman Why Might Thiazolidinediones Increase Exercise Capacity in Patients With Type 2 Diabetes? Diabetes Care, December 1, 2005; 28(12): 2975 - 2977. [Full Text] [PDF]